Table 5.
Predictors of PFS analyzed by multivariate Cox regression.
| Variable | B | SE | HR | 95% CI | P |
|---|---|---|---|---|---|
| Brain metastases at baseline (yes vs. no) | 0.130 | 0.341 | 1.138 | 0.583–2.221 | 0.704 |
| Molecular subtype | <0.001 | ||||
| (E709-T710delinsD vs. G719X) | 0.864 | 0.804 | 2.372 | 0.491–11.460 | 0.283 |
| (E709X vs. G719X) | -0.802 | 0.403 | 0.448 | 0.204–0.987 | 0.046 |
| (G724S vs. G719X) | 2.219 | 0.659 | 9.199 | 2.528–33.470 | 0.001 |
| Treatment patterns | 0.023 | ||||
| (CT vs. 2G TKI) | 0.874 | 0.382 | 2.398 | 1.135–5.066 | 0.022 |
| (1G TKI vs. 2G TKI) | 0.479 | 0.381 | 1.614 | 0.765–3.406 | 0.209 |
| (1G TKI + CT vs. 2G TKI) | -0.245 | 0.459 | 0.783 | 0.318–1.926 | 0.594 |
HR, hazard ratio; CI, confidence interval; TKI, tyrosine kinase inhibitors; CT, chemotherapy; 1G, first-generation; 2G, second-generation.